LUDHMILA ABRAHAO HAJJAR

(Fonte: Lattes)
Índice h a partir de 2011
41
Lattes
ResearcherID
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Clínica Médica, Faculdade de Medicina - Docente
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina
LIM/08 - Laboratório de Anestesiologia, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Revista / Livro: Journal of the American College of Cardiology ×

Resultados de Busca

Agora exibindo 1 - 10 de 12
  • conferenceObject
    CARDIOVASCULAR MORTALITY AND MYOCARDIAL INFARCTION AFTER RADIATION THERAPY FOR LEFT VERSUS RIGHT SIDED BREAST CANCER: A META-ANALYSIS
    (2016) BITTENCOURT, Marcio Sommer; VECSEY-NAGY, Milan; SANTOS, Marilia; SILVA, Carolina; FONSECA, Silvia M.; BITTAR, Cristina S.; HOFF, Paulo G.; KALIL-FILHO, Roberto; HAJJAR, Ludhmila A.
  • conferenceObject
    Endovascular Therapeutic Hypothermia Is Feasible as an Adjuvant Therapy in Acute ST-Segment Elevation Myocardial Infarction Patients Without Delay in Door-to-Balloon Time
    (2019) DALLAN, Luis; GIANNETTI, Natali; DAE, Michael; POLASTRI, Thatiane; ROCHITTE, Carlos Eduardo; NOMURA, Cesar Higa; HAJJAR, Ludhmila Abrahao; BERNOCHE, Claudia; LAGE, Silvia; LIMA, Felipe; NICOLAU, Jose Carlos; TAVARES JR., Mucio; RIBEIRO, Expedito; KALIL JR., Roberto; LEMOS, Pedro A.; TIMERMAN, Sergio
  • conferenceObject
    Cooling as an Adjunctive Therapy to Percutaneous Intervention in Acute Myocardial Infarction: COOL-MI InCor Trial
    (2020) DALLAN, Luis Augusto; GIANNETTI, Natali; ROCHITTE, Carlos Eduardo; POLASTRI, Thatiane; BERNOCHE, Claudia; HAJJAR, Ludhmila Abrahao; LIMA, Felipe; NICOLAU, Jose Carlos; TAVARES JR., Mucio; DAE, Michael; RIBEIRO, Expedito; KALIL JR., Roberto; LEMOS, Pedro A.; TIMERMAN, Sergio
  • article 0 Citação(ões) na Scopus
    Stress Echocardiography Another Hilltop, and It Is Better Than Ever
    (2023) MATHIAS, Wilson; BIHAN, David Costa de Souza Le; HAJJAR, Ludhmila Abrahao
  • conferenceObject
    THE BURDEN OF UNCONTROLLED CARDIOVASCULAR RISK FACTORS IN MEN WITH PROSTATE CANCER: A RADICAL PC ANALYSIS
    (2022) KLIMIS, Harry; PINTHUS, Jehonathan; SHAYEGAN, Bobby; KLOTZ, Laurence; SIEMENS, Robert; LUKE, Patrick; NIAZI, Tamim; FRADET, Vincet; DUCEPPE, Emmanuelle; LAVALLEE, Luke; MOUSAVI, Negareh; HAMILTON, Robert; BROWN, Ian; CHIN, Joseph; GOPAUL, Darin; VIOLETTE, Philippe; DAVIS, Margot; HANNA, Nawar; SABBAGH, Robert; ZADOK, Osnat Itzhaki Ben; SELVANAYAGAM, Joseph Brindaban; HAJJAR, Ludhmila; KANN, Ariel; LEONG, Darryl
  • article 10 Citação(ões) na Scopus
    Platelet Reactivity in Patients With Acute Coronary Syndromes Awaiting Surgical Revascularization
    (2021) NAKASHIMA, Carlos A. K.; DALLAN, Luis A. O.; LISBOA, Luiz A. F.; JATENE, Fabio B.; HAJJAR, Ludhmila A.; SOEIRO, Alexandre M.; FURTADO, Remo H. M.; DALCOQUIO, Talia F.; BARACIOLI, Luciano M.; LIMA, Felipe G.; V, Roberto R. C. Giraldez; SILVA, Bianca A.; COSTA, Mateus S. S.; STRUNZ, Celia M. C.; DALLAN, Luis R. P.; BARBOSA, Carlos J. D. G.; BRITTO, Flavia A. B.; FARKOUH, Michael E.; GURBEL, Paul A.; NICOLAU, Jose C.
    BACKGROUND Dual antiplatelet therapy is recommended for patients with acute coronary syndromes (ACS). Approximately 10% to 15% of these patients will undergo coronary artery bypass graft (CABG) surgery for index events, and current guidelines recommend stopping clopidogrel at least 5 days before CABG. This waiting time has clinical and economic implications. OBJECTIVES This study aimed to evaluate if a platelet reactivity-based strategy is noninferior to standard of care for 24-h post-CABG bleeding. METHODS In this randomized, open label noninferiority trial, 190 patients admitted with ACS with indications for CABG and on aspirin and P2Y(12) receptor inhibitors, were assigned to either control group, P2Y(12) receptor inhibitor withdrawn 5 to 7 days before CABG, or intervention group, daily measurements of platelet reactivity by Multiplate analyzer (Roche Diagnostics GmbH, Vienna, Austria) with CABG planned the next working day after platelet reactivity normalization (predefined as >= 46 aggregation units). RESULTS Within the first 24 h of CABG, the median chest tube drainage was 350 ml (interquartile range [IQR]: 250 to 475 ml) and 350 ml (IQR: 255 to 500 ml) in the intervention and control groups, respectively (p for noninferiority <0.001). The median waiting period between the decision to undergo CABG and the procedure was 112 h (IQR: 66 to 142 h) and 136 h (IQR: 112 to 161 h) (p < 0.001), respectively. In the intention-to-treat analysis, a 6.4% decrease in the median in-hospital expenses was observed in the intervention group (p = 0.014), with 11.2% decrease in the analysis per protocol (p = 0.003). CONCLUSIONS A strategy based on platelet reactivity-guided is noninferior to the standard of care in patients with ACS awaiting CABG regarding peri-operative bleeding, significantly shortens the waiting time to CABG, and decreases hospital expenses. (C) 2021 by the American College of Cardiology Foundation.
  • conferenceObject
    CARVEDILOL FOR PREVENTION OF CHEMOTHERAPY-INDUCED CARDIOTOXICITY: FINAL RESULTS OF THE PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CECCY TRIAL
    (2020) AYUB-FERREIRA, Silvia M.; AVILA, Monica; BRANDAO, Sara; CRUZ, Fatima D.; WANDERLEY JR., Mauro; RIGAUD, Vagner O. C.; HAJJAR, Ludhmila; KALIL-FILHO, Roberto; CRUZ, Cecilia B. V.; ALVES, Marco Stephan; GUIMARAES, Guilherme V.; ABDUCH, Maria; ISSA, Victor S.; SANTOS, Marilia; BITTENCOURT, Marcio; BOCCHI, Edimar Alcides
  • conferenceObject
    RELATIONSHIP BETWEEN ADMISSION TROPONIN AND OUTCOMES IN CRITICALLY ILL PATIENTS WITH HEART DISEASE AND COVID-19 IN A TERTIARY CENTER IN BRAZIL
    (2022) MOREIRA, Eduardo; PINESI, Henrique; VALDO, Melina; MARINS, Pedro Henrique; NASCIMENTO, Andre Luiz; ASSIS, Arthur; LIMA, Eduardo Gomes; PITTA, Fabio Grunspun; HAJJAR, Ludhmila; FERREIRA, Juliana; SERRANO JR., Carlos V.; GARZILLO, Cibele Larrosa
  • article 343 Citação(ões) na Scopus
    Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity
    (2018) AVILA, Monica Samuel; AYUB-FERREIRA, Silvia Moreira; WANDERLEY JR., Mauro Rogerio de Barros; CRUZ, Fatima das Dores; BRANDAO, Sara Michelly Goncalves; RIGAUD, Vagner Oliveira Carvalho; HIGUCHI-DOS-SANTOS, Marilia Harumi; HAJJAR, Ludhmila Abrahao; KALIL FILHO, Roberto; HOFF, Paulo Marcelo; SAHADE, Marina; FERRARI, Marcela S. M.; COSTA, Romulo Leopoldo de Paula; MANO, Max Senna; CRUZ, Cecilia Beatriz Bittencourt Viana; ABDUCH, Maria Cristina; ALVES, Marco Stephan Lofrano; GUIMARAES, Guilherme Veiga; ISSA, Victor Sarli; BITTENCOURT, Marcio Sommer; BOCCHI, Edimar Alcides
    BACKGROUND Anthracycline (ANT) chemotherapy is associated with cardiotoxicity. Prevention with beta-blockers remains controversial. OBJECTIVES This prospective, randomized, double-blind, placebo-controlled study sought to evaluate the role of carvedilol in preventing ANT cardiotoxicity. METHODS The authors randomized 200 patients with HER2-negative breast cancer tumor status and normal left ventricular ejection fraction (LVEF) referred for ANT (240 mg/m(2)) to receive carvedilol or placebo until chemotherapy completion. The primary endpoint was prevention of a >= 10% reduction in LVEF at 6 months. Secondary outcomes were effects of carvedilol on troponin I, B-type natriuretic peptide, and diastolic dysfunction. RESULTS Primary endpoint occurred in 14 patients (14.5%) in the carvedilol group and 13 patients (13.5%) in the placebo group (p = 1.0). No differences in changes of LVEF or B-type natriuretic peptide were noted between groups. A significant difference existed between groups in troponin I levels over time, with lower levels in the carvedilol group (p = 0.003). Additionally, a lower incidence of diastolic dysfunction was noted in the carvedilol group (p = 0.039). A nonsignificant trend toward a less-pronounced increase in LV end-diastolic diameter during the follow-up was noted in the carvedilol group (44.1 +/- 3.64 mm to 45.2 +/- 3.2 mm vs. 44.9 +/- 3.6 mm to 46.4 +/- 4.0 mm; p = 0.057). CONCLUSIONS In this largest clinical trial of beta-blockers for prevention of cardiotoxicity under contemporary ANT dosage, the authors noted a 13.5% to 14.5% incidence of cardiotoxicity. In this scenario, carvedilol had no impact on the incidence of early onset of LVEF reduction. However, the use of carvedilol resulted in a significant reduction in troponin levels and diastolic dysfunction.(Carvedilol Effect in Preventing Chemotherap-Induced Cardiotoxicity [CECCy] NCTO1724450)(C) 2018 by the American College of Cardiology Foundation.
  • conferenceObject
    THE ASSOCIATION OF ELECTRICAL LEFT AXIS DEVIATION WITH CARDIAC STRUCTURAL ABNORMALITIES IN PATIENTS WITH ADVANCED AGE: AN OBSERVATIONAL STUDY.
    (2023) TAVARES, Caio A. M.; SAMESIMA, Nelson; GUIMARAES, Patricia; PADRAO, Eduardo; FACIN, Mirella Esmanhotto; NETO, Felippe Lazar; FERREIRA, Elisa; HAJJAR, Ludhmila; PASTORE, Carlos Alberto